Cabaletta Bio, Inc. — Investor Relations & Filings
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company utilizes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) platform to develop treatments that aim to provide deep, durable, and potentially curative responses. Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to transiently eliminate B cells, thereby enabling an "immune system reset." Rese-cel is being advanced in Phase 1/2 clinical trials for a range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| 8-K - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English | |
| 424B5 - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English | |
| 8-K - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English |
Browse filings by year
9 yearsMarket data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Clinical-stage pharma company developing PP2A inhibitors to…
|
LIXT | US | Professional, scientific and te… |
|
Lunai Bioworks Inc.
Pre-clinical biotech company using AI for drug discovery an…
|
RENB | US | Professional, scientific and te… |
|
LYSOGENE
A former clinical-stage biotech that developed gene therapi…
|
LYS | FR | Professional, scientific and te… |
|
MaaT Pharma
A clinical-stage biotech developing microbiome-based therap…
|
MAAT | FR | Professional, scientific and te… |
|
Many Bright Ideas Technologies Inc.
Acquires, develops, and commercializes IP, emphasizing alte…
|
MBI.H | CA | Professional, scientific and te… |
|
MapLight Therapeutics, Inc.
Develops targeted therapies for CNS disorders using circuit…
|
MPLT | US | Professional, scientific and te… |
|
Marvel Biosciences Corp.
Developing transformative treatments for complex neurologic…
|
MRVL | CA | Professional, scientific and te… |
|
Matinas BioPharma Holdings, Inc.
Biopharma firm developing therapeutics using its Lipid Nano…
|
MTNB | US | Professional, scientific and te… |
|
Matricelf Ltd.
Develops autologous, patient-specific tissue implants for r…
|
MTLF | IL | Professional, scientific and te… |
|
MAXCYTE, INC.
A cell-engineering company with a platform for developing c…
|
MXCT | US | Professional, scientific and te… |
Cabaletta Bio, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33628/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33628 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33628 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33628 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33628}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cabaletta Bio, Inc. (id: 33628)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.